Residue Cys-67 of HLA-B27 contributes to antigen presentation and T cell recognition of HLA-B27 restricted T cell epitopes. by Appel, H, Kuhne, M, Kuon, W, Kuhlmann, S, Kollnberger, S, Weiss, E, Bowness, P, Sieper, J

Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. by Appel, H, Kuon, W, Kuhne, M, Wu, P, Kuhlmann, S, Kollnberger, S, Thiel, A, Bowness, P, Sieper, J

Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. by Appel, H, Kuon, W, Kuhne, M, Wu, P, Kuhlmann, S, Kollnberger, S, Thiel, A, Bowness, P, Sieper, J

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. by Rudwaleit, M, Claudepierre, P, Wordsworth, P, Cortina, E, Sieper, J, Kron, M, Carcereri-De-Prati, R, Kupper, H, Kary, S

The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes. by Appel, H, Kuon, W, Kuhne, M, Hülsmeyer, M, Kollnberger, S, Kuhlmann, S, Weiss, E, Zeitz, M, Wucherpfennig, K, Bowness, P, Sieper, J

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL by Wordsworth, P, van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Ballal, S, Kupper, H, Wong, R, Sieper, J

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-... by van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas by Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. by van der Heijde, D, Kivitz, A, Schiff, M, Sieper, J, Dijkmans, B, Braun, J, Dougados, M, Wordsworth, P, Wong, R, Kupper, H, Davis, J

Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. by Kuon, W, Holzhütter, H, Appel, H, Grolms, M, Kollnberger, S, Traeder, A, Henklein, P, Weiss, E, Thiel, A, Lauster, R, Bowness, P, Radbruch, A, Kloetzel, P, Sieper, J

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS by Emery, P, Baeten, D, Sieper, J, Braun, J, van der Heijde, D, McInnes, I, Van Laar, J, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Paramarta, I, Bertolino, A, Wright, A, Hueber, W

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS by Van Laar, J, Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, Landewe, R, Wordsworth, B, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Gsteiger, S, Hueber, W

Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions i... by Baeten, D, Bek, S, Wei, J, Brachat, A, Sieper, J, Emery, P, Braun, J, van der Heijde, D, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Bertolino, A, Wright, A, Wolfgang, H

LONG TERM INHIBITION OF IL-17A WITH SECUKINUMAB REDUCES SPINAL INFLAMMATION BUT HAS NO INFLUENCE ON FATTY LESIONS AS ASSESSED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOS... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W

Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with... by Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Wolfgang, H

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. by Baeten, D, Baraliakos, X, Braun, J, Sieper, J, Emery, P, van der Heijde, D, McInnes, I, van Laar, J, Landewé, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Paramarta, J, Wei, J, Brachat, A, Bek, S, Laurent, D, Li, Y, Wang, Y, Bertolino, A, Gsteiger, S, Wright, A, Hueber, W

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Resear... by Poddubnyy, D, Baraliakos, X, Van den Bosch, F, Braun, J, Coates, LC, Chandran, V, Diekhoff, T, van Gaalen, FA, Gensler, LS, Goel, N, Gottlieb, AB, van der Heijde, D, Helliwell, PS, Hermann, KGA, Jadon, D, Lambert, RG, Maksymowych, WP, Mease, P, Nash, P, Proft, F, Protopopov, M, Sieper, J, Torgutalp, M, Gladman, DD

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force by Smolen, JS, Schöls, M, Braun, J, Dougados, M, FitzGerald, O, Gladman, DD, Kavanaugh, A, Landewé, R, Mease, P, Sieper, J, Stamm, T, Wit, MD, Aletaha, D, Baraliakos, X, Betteridge, N, Bosch, FVD, Coates, LC, Emery, P, Gensler, LS, Gossec, L, Helliwell, P, Jongkees, M, Kvien, TK, Inman, RD, McInnes, IB, Maccarone, M, Machado, PM, Molto, A, Ogdie, A, Poddubnyy, D, Ritchlin, C, Rudwaleit, M, Tanew, A, Thio, B, Veale, D, Vlam, KD, van der Heijde, D